Dose‐dependent pharmacokinetics with single daily dose slow release theophylline in patients with chronic lung disease.

Butcher, MA; Frazer, LA; Reddel, Helen K.; Marlin, G. E.

doi:10.1111/j.1365-2125.1982.tb01368.x

Cited by 9 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concentrationdependence of theophylline clearance has been suggested as a result of disproportionate increases in plasma concentration in adults (Butcher et al, 1982;Jenne et al, 1972;Marlin et al, 1980) and children (Sarrazin et al, 1980;Weinberger & Ginchansky, 1977). Moreover, the formation of several theophylline metabolites has been shown to be saturable (Tang-Liu et al, 1982).…”

Section: Discussionmentioning

confidence: 99%

Influence of chronic dosing on theophylline clearance.

Efthimiou¹,

Morgan²,

Ioannides‐Demos³

et al. 1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

Theophylline clearance was studied in normal healthy volunteers before and after chronic oral dosing. Oral theophylline clearance showed a significant decrease (P less than 0.001) from 59.3 +/‐ 6.48 ml/min (mean +/‐ s.e. mean, n = 10) to 48.0 +/‐ 6.4 ml/min. Steady‐state intravenous clearance decreased by 26 +/‐ 2% from 55.1 +/‐ 7.7 ml/min to 41.0 +/‐ 5.96 ml/min (mean +/‐ s.e. mean, n = 6; P less than 0.001) at constant steady‐state intravenous test concentrations (mean 15.0 +/‐ 1.6 micrograms/ml after chronic oral dosing), excluding significant concentration dependence. Extrapolation of acute clearance findings to maintenance requirement may not be valid even in the same individual, with theophylline therapy requiring on‐going review beyond acute stabilisation.

show abstract

Section: Discussionmentioning

confidence: 99%

Influence of chronic dosing on theophylline clearance.

Efthimiou¹,

Morgan²,

Ioannides‐Demos³

et al. 1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…and thus cannot be described by simple linear models. A characteristic drug belonging to the aforementioned category (14)(15)(16)(17) is theophylline, a widely used drug with a narrow therapeutic range (55-110 umoles/l).…”

Section: Theophylline Eliminationmentioning

confidence: 99%

Individualization of theophylline infusion rate on the basis of a nonlinear compartmental pharmacokinetic model

Nikiforidis

Argyropoulos

Kassimatis

et al. 1997

European Journal of Drug Metabolism and Pharmacokinetics

View full text Add to dashboard Cite

In the present paper, a nonlinear compartmental model for theophylline pharmacokinetics is developed. The analytical solution of the model, in parametric form, is derived under plateau conditions for plasma metabolite concentration. The parameters are obtained from plasma and urine data using best fitting techniques and their values are used in order to calculate maintenance intravenous infusion. Numerical simulation is then performed in order to compare the drug concentration obtained by our approach with that of alternative intravenous regimens. The differences argue for individualized dosage regimens, since theophylline is a drug with a narrow therapeutic window and its concentration at the active sites strongly depends on characteristic parameters of the patient's response. Our results show that it is possible to estimate the patients' parameters during the first 8 h after intravenous administration of the drug and these parameters can be used to design an individualized dosage regimen in patients receiving theophylline intravenously.

show abstract